KR20210055469A - Whitening cosmetic composition comprising Sargassum serratifolium and poloxamer and use thereof - Google Patents
Whitening cosmetic composition comprising Sargassum serratifolium and poloxamer and use thereof Download PDFInfo
- Publication number
- KR20210055469A KR20210055469A KR1020190141947A KR20190141947A KR20210055469A KR 20210055469 A KR20210055469 A KR 20210055469A KR 1020190141947 A KR1020190141947 A KR 1020190141947A KR 20190141947 A KR20190141947 A KR 20190141947A KR 20210055469 A KR20210055469 A KR 20210055469A
- Authority
- KR
- South Korea
- Prior art keywords
- poloxamer
- present
- nanoemulsion
- cosmetic composition
- whitening
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 69
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 title claims abstract description 49
- 239000002537 cosmetic Substances 0.000 title claims abstract description 42
- 230000002087 whitening effect Effects 0.000 title claims abstract description 41
- 229920001983 poloxamer Polymers 0.000 title claims abstract description 38
- 229960000502 poloxamer Drugs 0.000 title claims abstract description 36
- 241000593948 Sargassum serratifolium Species 0.000 title claims abstract description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 71
- 239000007908 nanoemulsion Substances 0.000 claims abstract description 66
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 10
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims abstract description 7
- 239000004359 castor oil Substances 0.000 claims abstract description 6
- 239000011732 tocopherol Substances 0.000 claims abstract description 4
- 229930003799 tocopherol Natural products 0.000 claims abstract description 4
- 235000010384 tocopherol Nutrition 0.000 claims abstract description 4
- 229960001295 tocopherol Drugs 0.000 claims abstract description 4
- 235000019438 castor oil Nutrition 0.000 claims abstract 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims abstract 2
- 239000002245 particle Substances 0.000 claims description 24
- 239000000284 extract Substances 0.000 claims description 20
- 238000004519 manufacturing process Methods 0.000 claims description 13
- 235000013305 food Nutrition 0.000 claims description 12
- 229920001993 poloxamer 188 Polymers 0.000 claims description 8
- 229920001992 poloxamer 407 Polymers 0.000 claims description 8
- 229920002517 Poloxamer 338 Polymers 0.000 claims description 5
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 claims description 5
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 claims description 5
- 229940044519 poloxamer 188 Drugs 0.000 claims description 5
- 229940044476 poloxamer 407 Drugs 0.000 claims description 5
- HQPMKSGTIOYHJT-UHFFFAOYSA-N ethane-1,2-diol;propane-1,2-diol Chemical compound OCCO.CC(O)CO HQPMKSGTIOYHJT-UHFFFAOYSA-N 0.000 claims description 3
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 abstract description 30
- 230000008099 melanin synthesis Effects 0.000 abstract description 13
- 238000002156 mixing Methods 0.000 abstract description 6
- 238000009825 accumulation Methods 0.000 abstract description 5
- 230000003834 intracellular effect Effects 0.000 abstract 1
- 231100001083 no cytotoxicity Toxicity 0.000 abstract 1
- 238000000034 method Methods 0.000 description 24
- 210000003491 skin Anatomy 0.000 description 18
- 210000004027 cell Anatomy 0.000 description 17
- -1 methanol Alcohols Chemical class 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 239000002202 Polyethylene glycol Substances 0.000 description 11
- 239000003921 oil Substances 0.000 description 11
- 235000019198 oils Nutrition 0.000 description 11
- 229920001223 polyethylene glycol Polymers 0.000 description 11
- 239000002904 solvent Substances 0.000 description 11
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 10
- 239000000839 emulsion Substances 0.000 description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 102000003425 Tyrosinase Human genes 0.000 description 9
- 108060008724 Tyrosinase Proteins 0.000 description 9
- 210000002752 melanocyte Anatomy 0.000 description 9
- 238000003860 storage Methods 0.000 description 9
- 239000004480 active ingredient Substances 0.000 description 8
- 239000000796 flavoring agent Substances 0.000 description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 6
- 239000006071 cream Substances 0.000 description 6
- 230000003013 cytotoxicity Effects 0.000 description 6
- 231100000135 cytotoxicity Toxicity 0.000 description 6
- 238000010586 diagram Methods 0.000 description 6
- 235000014113 dietary fatty acids Nutrition 0.000 description 6
- 239000000469 ethanolic extract Substances 0.000 description 6
- 239000000194 fatty acid Substances 0.000 description 6
- 229930195729 fatty acid Natural products 0.000 description 6
- 235000013355 food flavoring agent Nutrition 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 229940088594 vitamin Drugs 0.000 description 6
- 229930003231 vitamin Natural products 0.000 description 6
- 235000013343 vitamin Nutrition 0.000 description 6
- 239000011782 vitamin Substances 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 102000003945 NF-kappa B Human genes 0.000 description 5
- 108010057466 NF-kappa B Proteins 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Natural products OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 206010014970 Ephelides Diseases 0.000 description 4
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 208000003351 Melanosis Diseases 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 210000005175 epidermal keratinocyte Anatomy 0.000 description 4
- 210000002615 epidermis Anatomy 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 239000002736 nonionic surfactant Substances 0.000 description 4
- 239000000049 pigment Substances 0.000 description 4
- 230000034190 positive regulation of NF-kappaB transcription factor activity Effects 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 3
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 3
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 208000012641 Pigmentation disease Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 150000005215 alkyl ethers Chemical class 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 210000002510 keratinocyte Anatomy 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 239000000693 micelle Substances 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 230000019612 pigmentation Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 229960000984 tocofersolan Drugs 0.000 description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 description 3
- 239000008158 vegetable oil Substances 0.000 description 3
- 235000004835 α-tocopherol Nutrition 0.000 description 3
- 239000002076 α-tocopherol Substances 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 2
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 2
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 2
- 101500011381 Oncorhynchus mykiss Melanocyte-stimulating hormone alpha 1 Proteins 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 239000010775 animal oil Substances 0.000 description 2
- 239000003945 anionic surfactant Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 235000005473 carotenes Nutrition 0.000 description 2
- 150000001746 carotenes Chemical class 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 235000019219 chocolate Nutrition 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000000287 crude extract Substances 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- RXKJFZQQPQGTFL-UHFFFAOYSA-N dihydroxyacetone Chemical compound OCC(=O)CO RXKJFZQQPQGTFL-UHFFFAOYSA-N 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- 150000002191 fatty alcohols Chemical class 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- DCAYPVUWAIABOU-UHFFFAOYSA-N hexadecane Chemical compound CCCCCCCCCCCCCCCC DCAYPVUWAIABOU-UHFFFAOYSA-N 0.000 description 2
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 230000001483 mobilizing effect Effects 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 229960001679 octinoxate Drugs 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 238000012261 overproduction Methods 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- DXGLGDHPHMLXJC-UHFFFAOYSA-N oxybenzone Chemical compound OC1=CC(OC)=CC=C1C(=O)C1=CC=CC=C1 DXGLGDHPHMLXJC-UHFFFAOYSA-N 0.000 description 2
- 229960001173 oxybenzone Drugs 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 229960002920 sorbitol Drugs 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 230000000475 sunscreen effect Effects 0.000 description 2
- 239000000516 sunscreening agent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- WWUZIQQURGPMPG-UHFFFAOYSA-N (-)-D-erythro-Sphingosine Natural products CCCCCCCCCCCCCC=CC(O)C(N)CO WWUZIQQURGPMPG-UHFFFAOYSA-N 0.000 description 1
- KZJWDPNRJALLNS-VPUBHVLGSA-N (-)-beta-Sitosterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@@H](C(C)C)CC)C)CC4)CC3)CC=2)CC1 KZJWDPNRJALLNS-VPUBHVLGSA-N 0.000 description 1
- HEOCBCNFKCOKBX-RELGSGGGSA-N (1s,2e,4r)-4,7,7-trimethyl-2-[(4-methylphenyl)methylidene]bicyclo[2.2.1]heptan-3-one Chemical compound C1=CC(C)=CC=C1\C=C/1C(=O)[C@]2(C)CC[C@H]\1C2(C)C HEOCBCNFKCOKBX-RELGSGGGSA-N 0.000 description 1
- CSVWWLUMXNHWSU-UHFFFAOYSA-N (22E)-(24xi)-24-ethyl-5alpha-cholest-22-en-3beta-ol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(CC)C(C)C)C1(C)CC2 CSVWWLUMXNHWSU-UHFFFAOYSA-N 0.000 description 1
- JSPNNZKWADNWHI-PNANGNLXSA-N (2r)-2-hydroxy-n-[(2s,3r,4e,8e)-3-hydroxy-9-methyl-1-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoctadeca-4,8-dien-2-yl]heptadecanamide Chemical compound CCCCCCCCCCCCCCC[C@@H](O)C(=O)N[C@H]([C@H](O)\C=C\CC\C=C(/C)CCCCCCCCC)CO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O JSPNNZKWADNWHI-PNANGNLXSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- MEZZCSHVIGVWFI-UHFFFAOYSA-N 2,2'-Dihydroxy-4-methoxybenzophenone Chemical compound OC1=CC(OC)=CC=C1C(=O)C1=CC=CC=C1O MEZZCSHVIGVWFI-UHFFFAOYSA-N 0.000 description 1
- WHQOKFZWSDOTQP-UHFFFAOYSA-N 2,3-dihydroxypropyl 4-aminobenzoate Chemical compound NC1=CC=C(C(=O)OCC(O)CO)C=C1 WHQOKFZWSDOTQP-UHFFFAOYSA-N 0.000 description 1
- TYYHDKOVFSVWON-UHFFFAOYSA-N 2-butyl-2-methoxy-1,3-diphenylpropane-1,3-dione Chemical compound C=1C=CC=CC=1C(=O)C(OC)(CCCC)C(=O)C1=CC=CC=C1 TYYHDKOVFSVWON-UHFFFAOYSA-N 0.000 description 1
- JGUMTYWKIBJSTN-UHFFFAOYSA-N 2-ethylhexyl 4-[[4,6-bis[4-(2-ethylhexoxycarbonyl)anilino]-1,3,5-triazin-2-yl]amino]benzoate Chemical compound C1=CC(C(=O)OCC(CC)CCCC)=CC=C1NC1=NC(NC=2C=CC(=CC=2)C(=O)OCC(CC)CCCC)=NC(NC=2C=CC(=CC=2)C(=O)OCC(CC)CCCC)=N1 JGUMTYWKIBJSTN-UHFFFAOYSA-N 0.000 description 1
- QWGRWMMWNDWRQN-UHFFFAOYSA-N 2-methylpropane-1,3-diol Chemical compound OCC(C)CO QWGRWMMWNDWRQN-UHFFFAOYSA-N 0.000 description 1
- KLEXDBGYSOIREE-UHFFFAOYSA-N 24xi-n-propylcholesterol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CCC)C(C)C)C1(C)CC2 KLEXDBGYSOIREE-UHFFFAOYSA-N 0.000 description 1
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 1
- 102100030310 5,6-dihydroxyindole-2-carboxylic acid oxidase Human genes 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 230000005653 Brownian motion process Effects 0.000 description 1
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- BHYOQNUELFTYRT-UHFFFAOYSA-N Cholesterol sulfate Natural products C1C=C2CC(OS(O)(=O)=O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 BHYOQNUELFTYRT-UHFFFAOYSA-N 0.000 description 1
- LPZCCMIISIBREI-MTFRKTCUSA-N Citrostadienol Natural products CC=C(CC[C@@H](C)[C@H]1CC[C@H]2C3=CC[C@H]4[C@H](C)[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C LPZCCMIISIBREI-MTFRKTCUSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- AERBNCYCJBRYDG-UHFFFAOYSA-N D-ribo-phytosphingosine Natural products CCCCCCCCCCCCCCC(O)C(O)C(N)CO AERBNCYCJBRYDG-UHFFFAOYSA-N 0.000 description 1
- 235000001809 DL-alpha-tocopherylacetate Nutrition 0.000 description 1
- 239000011626 DL-alpha-tocopherylacetate Substances 0.000 description 1
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 1
- ARVGMISWLZPBCH-UHFFFAOYSA-N Dehydro-beta-sitosterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCC(CC)C(C)C)CCC33)C)C3=CC=C21 ARVGMISWLZPBCH-UHFFFAOYSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- AHMIDUVKSGCHAU-UHFFFAOYSA-N Dopaquinone Natural products OC(=O)C(N)CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-UHFFFAOYSA-N 0.000 description 1
- 102000002045 Endothelin Human genes 0.000 description 1
- 108050009340 Endothelin Proteins 0.000 description 1
- 208000019028 Epidermal thickening Diseases 0.000 description 1
- FMRHJJZUHUTGKE-UHFFFAOYSA-N Ethylhexyl salicylate Chemical compound CCCCC(CC)COC(=O)C1=CC=CC=C1O FMRHJJZUHUTGKE-UHFFFAOYSA-N 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 102100031413 L-dopachrome tautomerase Human genes 0.000 description 1
- AHMIDUVKSGCHAU-LURJTMIESA-N L-dopaquinone Chemical compound [O-]C(=O)[C@@H]([NH3+])CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-LURJTMIESA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- YBGZDTIWKVFICR-JLHYYAGUSA-N Octyl 4-methoxycinnamic acid Chemical compound CCCCC(CC)COC(=O)\C=C\C1=CC=C(OC)C=C1 YBGZDTIWKVFICR-JLHYYAGUSA-N 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 206010051246 Photodermatosis Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 229920002690 Polyoxyl 40 HydrogenatedCastorOil Polymers 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical compound OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- MSCCTZZBYHQMQJ-AZAGJHQNSA-N Tocopheryl nicotinate Chemical compound C([C@@](OC1=C(C)C=2C)(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)CC1=C(C)C=2OC(=O)C1=CC=CN=C1 MSCCTZZBYHQMQJ-AZAGJHQNSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- MECHNRXZTMCUDQ-UHFFFAOYSA-N Vitamin D2 Natural products C1CCC2(C)C(C(C)C=CC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C MECHNRXZTMCUDQ-UHFFFAOYSA-N 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 206010047642 Vitiligo Diseases 0.000 description 1
- IPVNPUHVCZJVOI-VJSFXXLFSA-N [(3s,8s,9s,10r,13r,14s,17r)-17-[(2r,5r)-5-ethyl-6-methylheptan-2-yl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] hydrogen sulfate Chemical compound C1C=C2C[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 IPVNPUHVCZJVOI-VJSFXXLFSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- UBNYRXMKIIGMKK-RMKNXTFCSA-N amiloxate Chemical compound COC1=CC=C(\C=C\C(=O)OCCC(C)C)C=C1 UBNYRXMKIIGMKK-RMKNXTFCSA-N 0.000 description 1
- 229960004050 aminobenzoic acid Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 229960000271 arbutin Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 229960005193 avobenzone Drugs 0.000 description 1
- 235000021302 avocado oil Nutrition 0.000 description 1
- 239000008163 avocado oil Substances 0.000 description 1
- XVAMCHGMPYWHNL-UHFFFAOYSA-N bemotrizinol Chemical compound OC1=CC(OCC(CC)CCCC)=CC=C1C1=NC(C=2C=CC(OC)=CC=2)=NC(C=2C(=CC(OCC(CC)CCCC)=CC=2)O)=N1 XVAMCHGMPYWHNL-UHFFFAOYSA-N 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- MJVXAPPOFPTTCA-UHFFFAOYSA-N beta-Sistosterol Natural products CCC(CCC(C)C1CCC2C3CC=C4C(C)C(O)CCC4(C)C3CCC12C)C(C)C MJVXAPPOFPTTCA-UHFFFAOYSA-N 0.000 description 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- FQUNFJULCYSSOP-UHFFFAOYSA-N bisoctrizole Chemical compound N1=C2C=CC=CC2=NN1C1=CC(C(C)(C)CC(C)(C)C)=CC(CC=2C(=C(C=C(C=2)C(C)(C)CC(C)(C)C)N2N=C3C=CC=CC3=N2)O)=C1O FQUNFJULCYSSOP-UHFFFAOYSA-N 0.000 description 1
- 238000005537 brownian motion Methods 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 229930183167 cerebroside Natural products 0.000 description 1
- RIZIAUKTHDLMQX-UHFFFAOYSA-N cerebroside D Natural products CCCCCCCCCCCCCCCCC(O)C(=O)NC(C(O)C=CCCC=C(C)CCCCCCCCC)COC1OC(CO)C(O)C(O)C1O RIZIAUKTHDLMQX-UHFFFAOYSA-N 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000005827 chlorofluoro hydrocarbons Chemical class 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- BHYOQNUELFTYRT-DPAQBDIFSA-N cholesterol sulfate Chemical compound C1C=C2C[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 BHYOQNUELFTYRT-DPAQBDIFSA-N 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 238000004581 coalescence Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000001246 colloidal dispersion Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 229940086555 cyclomethicone Drugs 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- FDATWRLUYRHCJE-UHFFFAOYSA-N diethylamino hydroxybenzoyl hexyl benzoate Chemical compound CCCCCCOC(=O)C1=CC=CC=C1C(=O)C1=CC=C(N(CC)CC)C=C1O FDATWRLUYRHCJE-UHFFFAOYSA-N 0.000 description 1
- 229960001630 diethylamino hydroxybenzoyl hexyl benzoate Drugs 0.000 description 1
- OTKJDMGTUTTYMP-UHFFFAOYSA-N dihydrosphingosine Natural products CCCCCCCCCCCCCCCC(O)C(N)CO OTKJDMGTUTTYMP-UHFFFAOYSA-N 0.000 description 1
- 229940120503 dihydroxyacetone Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229940008099 dimethicone Drugs 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- 229940113120 dipropylene glycol Drugs 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- GLCJMPWWQKKJQZ-UHFFFAOYSA-L disodium;2-[4-(4,6-disulfonato-1h-benzimidazol-2-yl)phenyl]-1h-benzimidazole-4,6-disulfonate;hydron Chemical compound [Na+].[Na+].C1=C(S(O)(=O)=O)C=C2NC(C3=CC=C(C=C3)C3=NC4=C(C=C(C=C4N3)S(=O)(=O)O)S([O-])(=O)=O)=NC2=C1S([O-])(=O)=O GLCJMPWWQKKJQZ-UHFFFAOYSA-L 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 108010051081 dopachrome isomerase Proteins 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 229960004697 enzacamene Drugs 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 229960002061 ergocalciferol Drugs 0.000 description 1
- 229940068171 ethyl hexyl salicylate Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000005189 flocculation Methods 0.000 description 1
- 230000016615 flocculation Effects 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical class C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 1
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 1
- 229960004705 kojic acid Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000036564 melanin content Effects 0.000 description 1
- 210000002780 melanosome Anatomy 0.000 description 1
- ZGEGCLOFRBLKSE-UHFFFAOYSA-N methylene hexane Natural products CCCCCC=C ZGEGCLOFRBLKSE-UHFFFAOYSA-N 0.000 description 1
- WPHGSKGZRAQSGP-UHFFFAOYSA-N methylenecyclohexane Natural products C1CCCC2CC21 WPHGSKGZRAQSGP-UHFFFAOYSA-N 0.000 description 1
- 229940100573 methylpropanediol Drugs 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000013081 microcrystal Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- FMJSMJQBSVNSBF-UHFFFAOYSA-N octocrylene Chemical group C=1C=CC=CC=1C(=C(C#N)C(=O)OCC(CC)CCCC)C1=CC=CC=C1 FMJSMJQBSVNSBF-UHFFFAOYSA-N 0.000 description 1
- 229960000601 octocrylene Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000003961 penetration enhancing agent Substances 0.000 description 1
- 125000004817 pentamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000008845 photoaging Effects 0.000 description 1
- AERBNCYCJBRYDG-KSZLIROESA-N phytosphingosine Chemical compound CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@@H](N)CO AERBNCYCJBRYDG-KSZLIROESA-N 0.000 description 1
- 229940033329 phytosphingosine Drugs 0.000 description 1
- 210000004694 pigment cell Anatomy 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229940071089 sarcosinate Drugs 0.000 description 1
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- NLQLSVXGSXCXFE-UHFFFAOYSA-N sitosterol Natural products CC=C(/CCC(C)C1CC2C3=CCC4C(C)C(O)CCC4(C)C3CCC2(C)C1)C(C)C NLQLSVXGSXCXFE-UHFFFAOYSA-N 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- 235000015500 sitosterol Nutrition 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 230000037075 skin appearance Effects 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 230000037394 skin elasticity Effects 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- OTKJDMGTUTTYMP-ZWKOTPCHSA-N sphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@@H](N)CO OTKJDMGTUTTYMP-ZWKOTPCHSA-N 0.000 description 1
- WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000001256 steam distillation Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- CXVGEDCSTKKODG-UHFFFAOYSA-N sulisobenzone Chemical compound C1=C(S(O)(=O)=O)C(OC)=CC(O)=C1C(=O)C1=CC=CC=C1 CXVGEDCSTKKODG-UHFFFAOYSA-N 0.000 description 1
- 229960000368 sulisobenzone Drugs 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000013076 target substance Substances 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000011426 transformation method Methods 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- UEVAMYPIMMOEFW-UHFFFAOYSA-N trolamine salicylate Chemical compound OCCN(CCO)CCO.OC(=O)C1=CC=CC=C1O UEVAMYPIMMOEFW-UHFFFAOYSA-N 0.000 description 1
- 108010014402 tyrosinase-related protein-1 Proteins 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000001892 vitamin D2 Nutrition 0.000 description 1
- 239000011653 vitamin D2 Substances 0.000 description 1
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 1
- 235000005282 vitamin D3 Nutrition 0.000 description 1
- 239000011647 vitamin D3 Substances 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940021056 vitamin d3 Drugs 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9706—Algae
- A61K8/9711—Phaeophycota or Phaeophyta [brown algae], e.g. Fucus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/06—Emulsions
- A61K8/068—Microemulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/678—Tocopherol, i.e. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
- A61K8/86—Polyethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/202—Algae extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/41—Particular ingredients further characterized by their size
- A61K2800/413—Nanosized, i.e. having sizes below 100 nm
Abstract
Description
톱니모자반 및 폴록사머를 포함하는 미백용 화장료 조성물 및 이의 용도에 관한 것이다.It relates to a cosmetic composition for whitening comprising a sawtooth cap and poloxamer, and a use thereof.
사람의 피부색은 멜라닌, 카로틴 및 헤모글로빈의 양에 따라 결정되어 지는데 이중 멜라닌이 가장 결정적인 요소이다. 멜라닌은 피부(표피)내 기저층에 존재하는 색소세포인 멜라노사이트(melanocyte)에서 합성되며 주변 각질세포(Keratinocyte)로 전이되어 사람의 피부색을 나타낸다. 멜라닌이 비정상적으로 적게 생산되면 백반증(Vitiligo)과 같은 피부 병변이 유발된다. 반대로 과잉 생산은 중년 여성들의 주요 고민 중 하나인 기미, 주근깨를 형성하며 또한 피부안과도 밀접한 관계가 있다.Human skin color is determined by the amount of melanin, carotene and hemoglobin, of which melanin is the most decisive factor. Melanin is synthesized from melanocytes, pigment cells present in the base layer of the skin (epidermis), and metastasized to the surrounding keratinocytes to represent the color of human skin. Abnormally low production of melanin can lead to skin lesions such as vitiligo. Conversely, overproduction forms spots and freckles, which are one of the main concerns of middle-aged women, and is also closely related to skin ophthalmology.
미백 작용은, 멜라닌의 생성 및 축적을 억제하는 것이다. 멜라닌은 피부 표피의 기저층에 존재하는 멜라노사이트라는 세포에서 티로신(Tyrosine)이 효소 및 비효소적 산화반응을 거쳐 생성되며, 표피를 구성하고 있는 각질세포로 전이된다. 멜라닌의 생합성에 관여하는 중요한 효소로는 티로시나제(Tyrosinase), 티로시나제 관련 프로테인1(Tyrosinase-related protein 1) 및 도파크롬 토토머라제(dopachrome tautomerase)가 있다. 티로시나아제 외에 이 두 효소는 미백효과에 관해서 주목 받고 있는 효소이나, 멜라닌 합성에 결정적인 역할을 하는 효소는 티로시나아제이다. 멜라닌 생합성 첫단계는 티로시나아제에 의하여 유발된다. 티로시나아제에 의해 티로신이 도파(Dopa)로 되고 이 도파를 도파퀴논(Dopa-quinone)으로 만든다. 이 두 반응의 다음단계 과정들은 비효소적인 반응에 의해서도 가능한 것으로 알려져 있으며 티로시나아제 단독으로도 멜라닌 생성이 가능하다고 알려져 있다.The whitening action is to suppress the production and accumulation of melanin. Melanin is produced from cells called melanocytes in the base layer of the skin epidermis through enzyme and non-enzymatic oxidation reactions, and is transferred to keratinocytes constituting the epidermis. Important enzymes involved in the biosynthesis of melanin include tyrosinase, tyrosinase-
최근에는 피부 세포내의 신호 전달물질의 발현에 따른 멜라닌 형성과정에 대한 새로운 이론이 제시되고 있다. 피부가 자외선에 노출되면 염증을 유발시키는 인터루킨-알파가 케라티노사이트 엔도셀린(Endothelin) 발현을 촉진시킨다. 이러한 일련의 과정이 멜라노사이트의 형성을 증가시키고 멜라노사이트를 활성화시킨다. 이렇게 형성된 멜라노사이트내 멜라노좀에서 티로신이 티로시나아제에 의해 멜라닌이 형성된다.Recently, a new theory has been proposed for the process of melanin formation according to the expression of signal transducers in skin cells. When the skin is exposed to UV rays, interleukin-alpha, which causes inflammation, promotes the expression of keratinocyte Endothelin. This series of processes increases the formation of melanocytes and activates melanocytes. In the melanosomes in the melanocytes thus formed, tyrosine is formed by tyrosinase.
또한, NF-κB는 여러 가지 자극에 대해 응답적으로 활성화되어, 면역이나 세포증식, 염증 등에 관하여 여러 가지 유전자의 발현을 높여준다. NF-κB의 과잉 활성화가 암이나 류마티스, 건성 등과 관계있다는 것이 보고되어, 현재 세계적으로 NF-κB의 활성화를 억제하는 약제의 개발이 활발하게 이루어지고 있다. NF-κB는 피부의 표피각화세포나 진피 섬유아세포에도 존재하며, 자외선, 세포외 자극이나 염증성 사이토카인 등에 의해 NF-κB가 과잉으로 활성화됨으로써 염증과 세포사멸에 관련된 유전자들의 전사가 증가되는 것으로 확인되고 있다. NF-κB의 과잉활성화는 세포에서의 염증성 사이토카인들을 생성시키고 그 사이토카인들에 의해 더욱 NF-κB의 활성화가 일어난다. 또한, 세포증식인자인 bFGF(basic fibroblast growth factor)나 세포외 매트릭스 분해효소 MMP-1의 합성을 증가시켜 표피각화세포의 과증식이나 각화이상에 의한 표피의 비후, 멜라노사이트의 증식에 의한 색소침착, MMP-1의 진피 콜라겐 분해에 의한 피부 탄력의 저하 등을 일으킴으로써 피부의 광노화에도 관여한다.In addition, NF-κB is activated in response to various stimuli, thereby increasing the expression of various genes related to immunity, cell proliferation, and inflammation. It has been reported that excessive activation of NF-κB is related to cancer, rheumatism, dryness, and the like, and the development of drugs that inhibit the activation of NF-κB worldwide is currently being actively carried out. NF-κB is also present in epidermal keratinocytes and dermal fibroblasts of the skin, and it has been confirmed that the transcription of genes related to inflammation and apoptosis is increased by excessive activation of NF-κB by ultraviolet rays, extracellular stimulation, or inflammatory cytokines. Has become. Overactivation of NF-κB produces inflammatory cytokines in cells, and further activation of NF-κB occurs by these cytokines. In addition, by increasing the synthesis of bFGF (basic fibroblast growth factor) or extracellular matrix degrading enzyme MMP-1, which is a cell proliferation factor, hyperproliferation of epidermal keratinocytes or thickening of the epidermis due to keratinization abnormalities, pigmentation due to proliferation of melanocytes, It is also involved in photoaging of the skin by causing a decrease in skin elasticity and the like due to the decomposition of dermal collagen of MMP-1.
피부의 멜라닌 세포로서 색소를 만드는 표피 멜라노사이트 세포는 자외선이나 만성적인 염증 등의 자극에 의하여 피부에서 멜라닌 색소를 과잉으로 생성하여, 흑반, 기미, 주근깨 등의 원인이 되고 있다.Epidermal melanocyte cells, which make pigments as melanocytes of the skin, excessively produce melanin pigments in the skin due to stimulation such as ultraviolet rays or chronic inflammation, causing black spots, spots, freckles, and the like.
염증이나 자외선과 같은 외부자극에 의해 표피 각화세포에서는 NF-κB가 과잉으로 활성화되어 과잉의 멜라닌 생성을 유도하고, 표피 각화세포의 세포증식을 유도하는 bFGF의 생성을 촉진함으로써 표피의 비후, 멜라노사이트의 증식에 의한 색소침착을 유도한다. 따라서, NF-κB의 작용을 억제하는 물질은 염증이나 자외선에 의한 기미, 주근깨 등의 색소침착을 막는 효과를 나타낸다.NF-κB is excessively activated in epidermal keratinocytes by external stimuli such as inflammation or ultraviolet light, inducing excessive melanin production, and promoting the production of bFGF, which induces cell proliferation of epidermal keratinocytes, thereby promoting epidermal thickening and melanocytes. Induces pigmentation by proliferation of Therefore, a substance that inhibits the action of NF-κB exhibits an effect of preventing inflammation, spots caused by ultraviolet rays, and pigmentation such as freckles.
이미 아스코르빈산(특개평 4-9320), 하이드로퀴논(특개평 6-192062), 코직산(특개 56-7710), 알부틴(특개평4-9315) 및 일부의 화합물들이 티로시나제 저해 활성을 가지고 있어 미백 화장료의 원료로 이용되고 있으나, 처방계 중에서 안정성이 떨어져 분해되어 착색되거나, 이취의 발생, 생체 레벨에서의 효능, 효과의 불분명 및 안전성 문제 등으로 그 사용이 제한되고 있는 실정이다. 그리고 티로시나제의 억제 효과는 입증되었으나, 실제 생체 레벨과 유사한 실험에서는 그 효과가 낮게 나타나며 하이드로퀴논은 발암성 물질로 규정되어 사용이 금지되고 있다. 상기와 같은 이유들로 인해, 다양한 연구를 통해서, 염증과 같은 자극 반응을 일으키지 않으면서도 미백효과가 우수한 천연 추출물을 이용하고자 하는 연구가 진행되어 지고 있으며, 효과적으로 미백효과를 높이기 위한 방법이 개발되고 있다.Ascorbic acid (JP 4-9320), hydroquinone (JP 6-192062), kojic acid (JP 56-7710), arbutin (JP 4-9315) and some compounds have tyrosinase inhibitory activity to whiten. Although it is used as a raw material for cosmetics, its use is limited due to decomposition and coloration due to poor stability in the prescription system, the occurrence of off-flavor, efficacy at the biological level, unclear effect, and safety issues. In addition, although the inhibitory effect of tyrosinase has been proven, the effect is low in experiments similar to the actual biological level, and hydroquinone is regulated as a carcinogenic substance and its use is prohibited. For the above reasons, through various studies, studies to use natural extracts having excellent whitening effects without causing irritating reactions such as inflammation are being conducted, and methods for effectively enhancing whitening effects are being developed. .
에멀젼은 적어도 두 개 이상의 비혼합성 액체가 서로 섞이지 않고 작은 입자의 형태로 다른 액체에 분산되어 있는 콜로이드 분산계이다. 일반적으로 에멀젼은 열역학적으로 불안정한 상태이므로, 시간이 지남에 따라 응집 (Flocculation), 침강(Sedimentation), 크리밍(Creaming), 입자성장(Ostwald ripening) 및 유착(Coalescence)등과 같은 다양한 형태로 상이 분리되는 현상이 발생한다. 이러한 에멀젼의 불안정성 문제를 해결하기 위한 가장 단순하지만 효과적인 것으로 입자의 크기를 감소시키는 방법이 있다. 기본적으로 에멀젼의 입자 크기가 작아지면 상기에 언급한 다양한 현상을 비롯하여 중력의 영향을 덜 받아 입자들 사이에서 브라운 운동을 하게되고, 따라서 일반적인 에멀젼에 비하여 더 나은 분산 안정성을 제공한다.Emulsion is a colloidal dispersion system in which at least two non-mixed liquids are not mixed with each other and are dispersed in other liquids in the form of small particles. In general, emulsions are in a thermodynamically unstable state, so over time, phases are separated into various forms such as flocculation, sedimentation, creaming, particle growth, and coalescence. A phenomenon occurs. The simplest but most effective way to solve the problem of instability of the emulsion is a method of reducing the size of the particles. Basically, when the particle size of the emulsion becomes smaller, it is less affected by gravity, including the various phenomena mentioned above, and causes Brownian motion between the particles, thus providing better dispersion stability compared to a general emulsion.
따라서, 본 발명은 상기 종래기술들의 문제점들을 극복하기 위하여, 미백효과가 우수한 톱니모자반 및 폴록사머를 나노에멀젼으로 제조 하였으며, B16F10세포에 처리하여 세포독성 및 미백효과를 확인하였다. 또한 에멀젼 생성에 사용되는 폴록사머의 종류에 따라 생성되는 나노에멀젼의 크기 조절하여, 입자가 미세하고 입도가 고르게 분포되어 저장 안정도가 우수한 것을 확인함으로써 본 발명을 완성하였다.Therefore, in order to overcome the problems of the prior art, the present invention was prepared with a nanoemulsion of sawtooth hatch and poloxamer having excellent whitening effect, and the cytotoxicity and whitening effect were confirmed by treating B16F10 cells. In addition, the present invention was completed by controlling the size of the generated nanoemulsion according to the type of poloxamer used to generate the emulsion, and confirming that the particles are fine and the particle size is evenly distributed and thus has excellent storage stability.
본 발명의 목적은 톱니모자반(Sargassum serratifolium) 및 폴록사머(Poloxamer)를 포함하는, 미백용 화장료 조성물을 제공하는 것이다.An object of the present invention is to provide a cosmetic composition for whitening, comprising a sawtooth cap (Sargassum serratifolium) and poloxamer (Poloxamer).
본 발명의 다른 목적은 톱니모자반(Sargassum serratifolium) 및 폴록사머(Poloxamer)를 포함하는, 미백용 식품 조성물을 제공하는 것이다.Another object of the present invention is to provide a food composition for whitening, comprising a sawtooth cap (Sargassum serratifolium) and poloxamer.
본 발명의 또, 다른 목적은 Another object of the present invention is
(1)톱니모자반(Sargassum serratifolium)을 추출하는 단계;(1) Extracting the serratus plaque (Sargassum serratifolium);
(2)상기 톱니모자반 추출물에 폴록사머(poloxamer)를 추가하는 단계;(2) adding a poloxamer to the sawtooth capillary extract;
및And
(3) 상기 (2) 단계에 지용성 성분을 더 추가하여 나노에멀젼을 생성하는 단계;를 포함하는, 미백용 화장료 조성물의 제조방법을 제공하는 것이다.(3) generating a nanoemulsion by adding a fat-soluble component to the (2) step; containing, to provide a method for producing a cosmetic composition for whitening.
상기 목적을 달성하기 위하여, 본 발명은 톱니모자반(Sargassum serratifolium) 및 폴록사머(poloxamer)를 포함하는, 미백용 화장료 조성물을 제공한다. In order to achieve the above object, the present invention provides a cosmetic composition for whitening, comprising a sawtooth hatban (Sargassum serratifolium) and poloxamer (poloxamer).
또한, 본 발명의 다른 목적을 달성하기 위하여, 본 발명은 톱니모자반(Sargassum serratifolium) 및 폴록사머(poloxamer)를 포함하는, 미백용 식품 조성물을 제공한다. In addition, in order to achieve another object of the present invention, the present invention provides a whitening food composition comprising a sawtooth hatban (Sargassum serratifolium ) and poloxamer (poloxamer).
또한, 본 발명의 또 다른 목적을 달성하기 위하여, 본 발명은In addition, in order to achieve another object of the present invention, the present invention
(1)톱니모자반(Sargassum serratifolium)을 추출하는 단계;(1) Extracting the serratus plaque (Sargassum serratifolium);
(2)상기 톱니모자반 추출물에 폴록사머(poloxamer)를 추가하는 단계;(2) adding a poloxamer to the sawtooth capillary extract;
및And
(3) 상기 (2) 단계에 지용성 성분을 더 추가하여 나노에멀젼을 생성하는 단계;를 포함하는, 미백용 화장료 조성물의 제조방법을 제공한다. (3) generating a nanoemulsion by adding a fat-soluble component to the (2) step; containing, it provides a method for producing a cosmetic composition for whitening.
본 발명은 미백효능이 우수한 유효물질로서 톱니모자반 및 폴록사머를 포함하는 나노에멀젼, 이의 제조방법, 이를 유효성분으로 함유하는 미백용 화장료 조성물에 관한 것으로, 본 발명에 따른 톱니모자반, 폴록사머 및 피부침투 촉진제를 포함하는 나노에멀젼은, 멜라닌 생합성 억제 및 세포내 멜라닌 축적을 감소시킴으로서 효과적으로 미백효능을 나타내고, 유효성분의 산화를 억제하여 저장 안정성이 우수한 복합 기능성 화장료 조성물로 유용하게 사용할 수 있다.The present invention relates to a nanoemulsion comprising a toothed cap and poloxamer as an effective material with excellent whitening effect, a method for preparing the same, and a cosmetic composition for whitening containing the same as an active ingredient, and to a toothed cap, poloxamer and skin according to the present invention The nanoemulsion containing a penetration enhancer effectively exhibits whitening effect by inhibiting melanin biosynthesis and reducing melanin accumulation in cells, and can be usefully used as a complex functional cosmetic composition having excellent storage stability by inhibiting oxidation of active ingredients.
도 1은 본 발명의 나노에멀젼 제조방법에 있어서, 첨가되는 토코페놀의 함량에 따른 나노에멀젼의 입자 크기를 비교한 도이다. A는 토코페놀 0 g, B는 토코페놀 0.02 g, C는 토코페놀 0.05 g 및 D는 0.1 g 첨가하여 제조된 나노에멀젼의 입자크기를 비교하였다.
도 2는 본 발명의 나노에멀젼 제조방법에 있어서, 희석에 사용된 에탄올의 함량에 따른 나노에멀젼의 입자 크기를 비교한 도이다. A는 에탄올 2 ml, B는 에탄올 4.5 ml, C는 에탄올 9.5 ml D는 에탄올 19.5 ml로 희석하여 제조된 나노에멀젼의 입자크기를 비교하였다.
도 3은 본 발명의 나노에멀젼 제조방법에 있어서, 첨가되는 PEG400의 함량에 따른 나노에멀젼의 입자 크기를 비교한 도이다. A는 PEG 0 g, B는 PEG 0.3 g을 첨가하여 제조된 나노에멀젼의 크기를 비교하였다.
도 4은 본 발명의 나노에멀젼 제조방법에 있어서, 첨가되는 폴록사머의 종류에 따른 나노에멀젼의 입자 크기를 비교한 도이다. A는 폴록사머 407 (Pluronic F127)을 1 g, B는 폴록사머 188 (Pluronic F68)을 1 g, C는 폴록사머 338 (Pluronic F108)을 1 g 첨가하여 제조된 나노에멀젼의 크기를 비교하였다.
도 5는 본 발명의 나노에멀젼의 보관 일수에 따른 저장안정성을 육안 관찰한 도이다.
도 6는 본 발명의 나노에멀젼을 B16F10 세포에 농도별로 처리하여, 세포독성을 확인한 도이다.
도 7는 본 발명의 나노에멀젼을 B16F10 세포에 농도별로 처리하여, 멜라닌 생합성 저해 효과를 확인한 도이다. 1 is a diagram comparing the particle size of the nanoemulsion according to the amount of tocophenol added in the nanoemulsion manufacturing method of the present invention. A was tocophenol 0 g, B was tocophenol 0.02 g, C was tocophenol 0.05 g and D was compared to the particle size of the nanoemulsion prepared by adding 0.1 g.
2 is a diagram comparing the particle size of the nanoemulsion according to the content of ethanol used for dilution in the nanoemulsion manufacturing method of the present invention. A is 2 ml of ethanol, B is 4.5 ml of ethanol, C is 9.5 ml of ethanol and D is diluted with 19.5 ml of ethanol to compare the particle sizes of the nanoemulsions prepared.
3 is a diagram comparing the particle size of the nanoemulsion according to the amount of PEG400 added in the nanoemulsion manufacturing method of the present invention. A was PEG 0 g, B was compared to the size of the nanoemulsion prepared by adding PEG 0.3 g.
4 is a view comparing the particle size of the nanoemulsion according to the type of poloxamer added in the nanoemulsion manufacturing method of the present invention. A is poloxamer 407 (Pluronic F127) 1 g, B is poloxamer 188 (Pluronic F68) 1 g, C is poloxamer 338 (Pluronic F108) 1 g was added to compare the size of the prepared nanoemulsion.
5 is a diagram illustrating the storage stability according to the storage days of the nanoemulsion of the present invention with the naked eye.
6 is a diagram illustrating cytotoxicity by treating the nanoemulsion of the present invention by concentration in B16F10 cells.
7 is a diagram illustrating the effect of inhibiting melanin biosynthesis by treating the nanoemulsion of the present invention by concentration in B16F10 cells.
이하, 본 발명을 상세히 설명한다.Hereinafter, the present invention will be described in detail.
본 발명은 톱니모자반(Sargassum serratifolium) 및 폴록사머(poloxamer)를 포함하는, 미백용 화장료 조성물을 제공한다.The present invention provides a cosmetic composition for whitening, comprising a sawtooth cap (Sargassum serratifolium) and poloxamer (poloxamer).
본 발명에서 사용되는 용어 “조성물”은 목적 물질을 생산하기 위한 다양한 물질을 혼합한 것으로서, 유효성분, 유화제, 미네랄오일, 향료 및 방부제 등이 포함된 것을 의미한다. The term “composition” used in the present invention refers to a mixture of various substances for producing a target substance, and includes active ingredients, emulsifiers, mineral oils, flavors and preservatives.
또한, 본 발명에서 사용되는 용어 “미백”은 피부 및 신체의 외적인 부분에 있어서, 하얗게 하는 것을 뜻하며, 멜라닌 생성의 억제 및 멜라닌 축적의 감소가 동반되는 것을 의미한다.In addition, the term "whitening" used in the present invention means whitening of the skin and external parts of the body, and it means that inhibition of melanin production and reduction of melanin accumulation are accompanied.
본 발명에 사용한 톱니모자반은 부산시 기장군에서 자생하는 천연산을 스쿠버를 동원하여 채취하였고, 채취한 톱니모자반은, 종 분석을 시행하여 본 발명에 사용하였다.The sawtooth hat plate used in the present invention was collected by scuba mobilizing a natural product that grows in Gijang-gun, Busan, and the collected sawtooth hat plate was used in the present invention by performing a species analysis.
본 발명의 미백용 화장료 조성물은, 멜라닌 생성 및 세포내 축적을 억제하는 조성물로서, 멜라닌은 피부에 존재하는 색소로 자외선 등 외부의 자극으로부터 신체를 보호하는 중요한 기능을 한다. 하지만 이것이 과잉 생성되어 침착되면 기미나 주근깨 등을 형성시켜 피부 외관상 문제를 야기할 수 있으며, 나아가 피부노화를 촉진시켜 피부암을 유발할 수 있기 때문에 멜라닌 과잉생성을 억제할 수 있는 물질의 경우 미백용 화장료 조성물로 사용 될 수 있다.The cosmetic composition for whitening of the present invention is a composition that suppresses the production of melanin and accumulation in cells, and melanin is a pigment present in the skin and serves an important function of protecting the body from external stimuli such as ultraviolet rays. However, if this is excessively generated and deposited, it can cause skin appearance problems by forming spots or freckles, and furthermore, it can promote skin aging and cause skin cancer.Therefore, in the case of substances that can suppress the overproduction of melanin, a cosmetic composition for whitening Can be used as.
본 발명의 일 실시례에 따르면, 본 발명의 톱니모자반 및 폴록사머를 사용하여 제조된 나노에멀젼을 B16F10 세포에 처리하여, 멜라닌 생합성이 100% 억제되는 것을 확인하였다(실시예 16 및 도 7). According to an embodiment of the present invention, it was confirmed that 100% of melanin biosynthesis was inhibited by treating the nanoemulsion prepared using the sawtooth hatch and poloxamer of the present invention on B16F10 cells (Example 16 and FIG. 7).
따라서, 본 발명은 톱니모자반 및 폴록사머를 포함하는 나노에멀젼 및 이를 유효성분으로 포함하는 피부 미백 화장료 조성물을 제공할 수 있다.Accordingly, the present invention can provide a nanoemulsion comprising a sawtooth hatch and poloxamer, and a skin whitening cosmetic composition comprising the same as an active ingredient.
상기 본 발명의 톱니모자반은 에탄올로 추출된 톱니모자반 추출물인 것인 미백용 화장료 조성물일 수 있다.The toothed cap of the present invention may be a cosmetic composition for whitening that is an extract of toothed caps extracted with ethanol.
본 발명에 따른 톱니모자반 추출물은 당업계에 공지된 추출 및 분리하는 방법을 사용하여 천연으로부터 추출 및 분리하여 수득한 것을 사용할 수 있으며, 본 발명에서 정의된 추출물은 적절한 용매를 이용하여 톱니모자반으로 부터 추출한 것이며, 예를 들어, 톱니모자반의 조추출물, 극성용매 가용 추출물 또는 비극성용매 가용 추출물을 모두 포함한다.The extract according to the present invention may be obtained by extracting and separating from nature using a method known in the art for extraction and separation, and the extract defined in the present invention may be used from the sawtooth plaque using an appropriate solvent. It is extracted, and includes, for example, a crude extract of sawtooth hatch, an extract soluble in a polar solvent, or an extract soluble in a non-polar solvent.
상기 톱니모자반으로부터 추출물을 추출하기 위한 적절한 용매로는 약학적으로 허용되는 유기용매라면 어느 것을 사용해도 무방하며, 물 또는 유기용매를 사용할 수 있으며, 이에 제한되지는 않으나, 예를 들어, 정제수, 메탄올(methanol), 에탄올(ethanol), 프로판올(propanol), 이소프로판올(isopropanol), 부탄올(butanol) 등을 포함하는 탄소수 1 내지 4의 알코올, 아세톤(acetone), 에테르(ether), 벤젠(benzene), 클로로포름(chloroform), 에틸아세테이트(ethyl acetate), 메틸렌클로라이드(methylene chloride), 헥산(hexane) 및 시클로헥산 (cyclohexane) 등의 각종 용매를 단독으로 혹은 혼합하여 사용할 수 있다. 바람직하게는 에탄올, 부탄올 또는 에틸아세테이트이며, 더욱 바람직하게는 에탄올이나 이에 제한된 것은 아니다. Any suitable solvent for extracting the extract from the sawtooth hatch spot may be used as long as it is a pharmaceutically acceptable organic solvent, and water or an organic solvent may be used, but is not limited thereto, for example, purified water, methanol Alcohols having 1 to 4 carbon atoms, including (methanol), ethanol, propanol, isopropanol, butanol, etc., acetone, ether, benzene, chloroform Various solvents such as (chloroform), ethyl acetate, methylene chloride, hexane, and cyclohexane may be used alone or in combination. Preferably ethanol, butanol or ethyl acetate, more preferably ethanol, but not limited thereto.
추출 방법으로는 열수추출법, 냉침추출법, 환류냉각추출법, 용매추출법, 수증기증류법, 초음파추출법, 용출법, 압착법 등의 방법 중 어느 하나를 선택하여 사용할 수 있다. 또한, 목적하는 추출물은 추가로 통상의 분획 공정 을 수행할 수도 있으며, 통상의 정제 방법을 이용하여 정제될 수도 있다. 본 발명의 톱니모자반 추출물의 제조 방법에는 제한이 없으며, 공지되어 있는 어떠한 방법도 이용될 수 있다. As the extraction method, any one of methods such as hot water extraction, cold precipitation extraction, reflux cooling extraction, solvent extraction, steam distillation method, ultrasonic extraction method, elution method, and compression method may be used. In addition, the desired extract may be further subjected to a conventional fractionation process, or may be purified using a conventional purification method. There is no limitation on the method for preparing the sawtooth capillary extract of the present invention, and any known method may be used.
본 발명에 있어서 톱니모자반 추출물은 추출, 분획 또는 정제의 각 단계에서 얻어지는 모든 추출액, 분획 및 정제물, 그들의 희석액, 농축액 또는 건조물을 모두 포함하는 개념이다. In the present invention, the sawtooth capillary extract is a concept including all extracts, fractions and purified products obtained in each step of extraction, fractionation, or purification, and their dilutions, concentrates, or dried products.
상기 본 발명의 폭록사머는, 폴록사머 407 (Pluronic F-127), 폴록사머 188 (Pluronic F68) 및 폴록사머 338 (Pluronic F108)로 이루어진 군에서 선택된 1종 이상인 것인, 미백용 화장료 조성물일 수 있다.The poxamer of the present invention is one or more selected from the group consisting of poloxamer 407 (Pluronic F-127), poloxamer 188 (Pluronic F68), and poloxamer 338 (Pluronic F108), which may be a cosmetic composition for whitening. have.
본 발명의 폴록사머는 비이온성 계면활성제로서, 당업계에 공지된 어떠한 계면활성제라도 사용될 수 있다. 바람직하게는 음이온성 계면활성제 및 비이온성 계면활성제이다. 음이온성 계면활성제의 구체적인 예는 알킬아실글루타메이트, 알킬포스페이트, 알킬락틸레이트, 디알킬포스페이트 및 트리알킬포스페이트를 포함한다. 비이온성 계면활성제의 구체적인 예는 폴록사머, 알콕시레이티드 알킬에테르, 알콕시레이티드 알킬에스테르, 알킬폴리글리코사이드, 폴리글리세릴에스테르 및 슈가에스테르를 포함한다. 더욱 바람직한 계면활성제는 비이온성 계면활성제에 속하는 폴록사머이나 이제 제한되지는 않는다.The poloxamer of the present invention is a nonionic surfactant, and any surfactant known in the art may be used. Preferably, they are anionic surfactants and nonionic surfactants. Specific examples of the anionic surfactant include alkylacyl glutamate, alkyl phosphate, alkyl lactylate, dialkyl phosphate and trialkyl phosphate. Specific examples of nonionic surfactants include poloxamers, alkoxylated alkyl ethers, alkoxylated alkyl esters, alkyl polyglycosides, polyglyceryl esters and sugar esters. More preferred surfactants are poloxamers, which belong to nonionic surfactants, but are now not limited.
또한 상기 조성물은 입자크기 15 내지 40 nm의 나노에멀젼인 것인, 미백용 화장료 조성물일 수 있다.In addition, the composition may be a cosmetic composition for whitening, which is a nanoemulsion having a particle size of 15 to 40 nm.
본 발명에서 사용되는 용어“에멀젼”은 액체가 다른 액체에 작은 방울처럼 퍼져있는 용액을 뜻하며, 지용성 및 수용성 용액을 혼합하여, 미셀(micelle)이 형성되어 있는 상태를 의미한다.The term “emulsion” used in the present invention refers to a solution in which a liquid is spread like small droplets in another liquid, and refers to a state in which micelles are formed by mixing oil-soluble and water-soluble solutions.
본 발명에서 나노에멀젼은 통상적인 미셀(micelle)의 형태를 가지며 평균 입자 지름이 10 내지 200 nm인 미셀을 의미한다. 본 발명의 바람직한 구현 예에 따르면, 나노에멀젼의 평균 입자 지름은 10 내지 80 nm이며, 더욱 바람직하게는 15 내지 40 nm이다. 나노에멀젼의 평균 입자 크기가 80 nm를 초과하는 경우에는 피부침투 및 제형 안정성이 감소하게 된다. In the present invention, the nanoemulsion refers to a micelle having an average particle diameter of 10 to 200 nm in the form of a conventional micelle. According to a preferred embodiment of the present invention, the average particle diameter of the nanoemulsion is 10 to 80 nm, more preferably 15 to 40 nm. When the average particle size of the nanoemulsion exceeds 80 nm, skin penetration and formulation stability decrease.
본 발명의 나노에멀젼의 제조에는 폴리올, 지용성 성분, 계면활성제, 인지질, 지방산 및 물을 포함하는 통상의 나노에멀젼 제조에 이용되는 혼합물에 의해 제조될 수 있다. In the preparation of the nanoemulsion of the present invention, it may be prepared by a mixture used for preparing a conventional nanoemulsion comprising a polyol, a fat-soluble component, a surfactant, a phospholipid, a fatty acid, and water.
본 발명에서 사용되는 용어 “혼합물”은 용매 혹은 용질 등 2이상의 물질이 고르게 분포되어 있는 것을 뜻하며, 용매와 용매의 혼합 및 용매와 용질의 혼합과 같이 다양한 제제가 혼합되어 있는 상태의 물질을 의미한다.The term “mixture” used in the present invention means that two or more substances such as a solvent or a solute are evenly distributed, and refers to a substance in which various agents are mixed, such as a solvent and a solvent and a solvent and a solute. .
또한 상기 조성물은 지용성 성분을 더 포함할 수 있으며, 토코페롤, PEG400, 폴리옥실-35-캐스터오일, 및 폴리옥실-40-하이드로제네이티드캐스터오일로 이루어진 군에서 선택된 1종 이상을 포함하는 것인, 미백용 화장료 조성물일 수 있다. 상기 본 발명의 지용성 성분은 당업계에 공지된 다양한 오일이 이용될 수 있으며, 헥사데칸 및 파라핀 오일과 같은 하이드로카본계 오일, 캐스터오일, 에스테르계의 합성오일, 디메치콘 및 사이크로메치콘계와 같은 실리콘 오일, 해바라기유, 옥수수유, 대두유, 아보카도유, 참깨유 및 어유와 같은 동식물성 오일, 에톡시레이티드 알킬에테르계오일, 프로폭시레이티드 알킬에테르계오일, 피토스핑고신, 스핑고신 및 스핑가닌과 같은 스핑고노이드 지질, 세레브로사이드 콜레스테롤, 시토스테롤 콜레스테릴설페이트, 시토스테릴설페이트, C10-40 지방알콜 및 이의 혼합물이나 이에 제한되지는 않는다.In addition, the composition may further contain a fat-soluble component, and tocopherol, PEG400, polyoxyl-35-castor oil, and polyoxyl-40-hydrogenated castor oil, which comprises at least one selected from the group consisting of, It may be a cosmetic composition for whitening. Various oils known in the art may be used as the fat-soluble component of the present invention, and hydrocarbon oils such as hexadecane and paraffin oils, castor oils, ester-based synthetic oils, dimethicone and cyclomethicone oils. Animal and vegetable oils such as silicone oil, sunflower oil, corn oil, soybean oil, avocado oil, sesame oil and fish oil, ethoxylated alkyl ether oil, propoxylated alkyl ether oil, phytosphingosine, sphingosine and Sphingonoid lipids such as sphinganine, cerebroside cholesterol, sitosterol cholesterol sulfate, sitosterol sulfate, C10-40 fatty alcohol and mixtures thereof, but are not limited thereto.
본 발명의 지용성 성분 제조에 있어서 지용성 비타민류가 더 포함될 수 있으며, 지용성 비타민으로서는 지용성 용매에 용해 가능한 것이라면 어떠한 것이라도 되지만, 바람직하게는 비타민 A, 카로틴, 비타민 D2, 비타민 D3, 비타민 E (d1-알파 토코페롤, d-알파 토코페롤, d-알파 토코페롤) 등을 들 수 있으며, 그들의 유도체(팔미틴산아스코르빈, 스테아르산아스코르빈, 디팔미틴산아스코르빈, 아세트산dl-알파 토코페롤, 니코틴산dl-알파 토코페롤비타민 E, DL-판토테닐알코올, D-판토테닐알코올, 판토테닐에틸에테르 등) 등도 본 발명에서 사용되는 유용성 비타민에 포함되며 더욱 바람직하게는 토코페롤이나 이에 제한되지는 않는다. 유용성 비타민은 미생물 변환법, 미생물의 배양물로부터의 정제법, 효소 또는 화학 합성법 등의 통상의 방법에 의해 취득할 수 있다.Fat-soluble vitamins may be further included in the preparation of the fat-soluble component of the present invention, and any fat-soluble vitamin may be used as long as it is soluble in a fat-soluble solvent, but preferably vitamin A, carotene, vitamin D2, vitamin D3, vitamin E (d1- Alpha tocopherol, d-alpha tocopherol, d-alpha tocopherol), and their derivatives (ascorbine palmitate, ascorbine stearate, ascorbine dipalmitate, dl-alpha tocopherol acetate, dl-alpha tocopherol nicotinate) Vitamin E, DL-pantotenyl alcohol, D-pantotenyl alcohol, pantotenyl ethyl ether, etc.) are also included in the oil-soluble vitamins used in the present invention, more preferably tocopherol, but is not limited thereto. Oil-soluble vitamins can be obtained by conventional methods such as a microbial transformation method, a purification method from a culture of microorganisms, an enzyme or chemical synthesis method.
본 발명의 나노에멀젼 제조에 있어서, 폴리올이 더 포함 될 수 있으며, 폴리에틸렌 글리콜(PEG), 프로필렌글리콜, 디프로필렌글리콜, 1,3-부틸렌글리콜, 글리세린, 메틸프로판디올, 이소프로필렌글리콜, 펜틸렌글리콜, 에리스리톨, 자일리톨, 솔비톨 및 이의 혼합물로 구성된 군으로부터 선택된 1종 이상이며, 바람직하게는 PEG이나, 이에 제한되지는 않는다. In the preparation of the nanoemulsion of the present invention, a polyol may be further included, and polyethylene glycol (PEG), propylene glycol, dipropylene glycol, 1,3-butylene glycol, glycerin, methylpropanediol, isopropylene glycol, pentylene It is at least one selected from the group consisting of glycol, erythritol, xylitol, sorbitol, and mixtures thereof, preferably PEG, but is not limited thereto.
본 발명의 나노에멀전 제조에 이용되는 물은 일반적으로 탈이온화된 증류수이일 수 있다.The water used to prepare the nanoemulsion of the present invention may generally be deionized distilled water.
이와 같이 톱니모자반 및 폴록사머를 유효성분으로 함유하는 나노에멀젼은 화장품 조성물로 제조되는 경우, 화장료 조성물에 통상적으로 이용되는 성분들을 포함할 수 있으며, 예컨대 항산화제, 안정화제, 용해화제, 미타민, 안료 및 향료와 같은 통상적인 보조제, 그리고 담체를 포함할 수 있다.In this way, the nanoemulsion containing sawtooth hatch and poloxamer as active ingredients, when prepared as a cosmetic composition, may include ingredients commonly used in cosmetic compositions, such as antioxidants, stabilizers, solubilizers, mitamine, Conventional adjuvants such as pigments and fragrances, and carriers may be included.
또한, 본 발명의 조성물은 상술한 나노에멀젼 이외에, 나노에멀젼과 반응하여 피부보호효과를 손상시키지 않는 한도에서 종래부터 사용되어 오던 유기 자외선 차단제를 혼합하여 사용할 수도 있다.In addition, in addition to the above-described nanoemulsion, the composition of the present invention may be used by mixing an organic sunscreen that has been conventionally used as long as it reacts with the nanoemulsion and does not impair the skin protective effect.
유기 자외선 차단제로는 글리세릴파바, 드로메트리졸트리실록산, 드로메트리졸, 디갈로일트리올리에이트, 디소 듐페닐디벤즈이미다졸테트라설포네이트, 디에칠헥실부타미도트리아존, 디에칠아미노하이드록시벤조일헥실벤조에 이트, 디이에이-메톡시신나메이트, 로우손과 디하이드록시아세톤의 혼합물, 메칠렌비스-벤조트리아졸릴테트라메 칠부틸페놀, 4-메칠벤질리덴캠퍼, 멘틸안트라닐레이트, 벤조페논-3(옥시벤존),벤조페논-4, 벤조페논-8(디옥시페 벤존), 부틸메톡시디벤조일메탄, 비스에칠헥실옥시페놀메톡시페닐트리아진, 시녹세이트, 에칠디하이드록시프로 필파바, 옥토크릴렌, 에칠헥실디메칠파바, 에칠헥실메톡시신나메이트, 에칠헥실살리실레이트, 에칠헥실트리아존, 이소아밀-p-메톡시신나메이트, 폴리실리콘-15(디메치코디에칠벤잘말로네이트), 테레프탈릴리 덴디캠퍼설포닉애씨드 및 그 염류, 티이에이-살리실레이트 및 아미노벤조익애씨드(파바)로 이루어진 군으로부터 선택된 1종 이상을 사용할 수 있다.Organic sunscreens include glycerylpaba, dromethrizoltrisiloxane, dromethrizol, digaloyltrioleate, disodium phenyldibenzimidazole tetrasulfonate, diethhexylbutamidotriazone, diethylaminohydroxy Benzoylhexylbenzoate, DieA-methoxycinnamate, mixture of Lawson and dihydroxyacetone, methylenebis-benzotriazolyltetramethylbutylphenol, 4-methylbenzylidene camphor, menthylanthranylate, benzo Phenone-3 (oxybenzone), benzophenone-4, benzophenone-8 (dioxyfebenzoyl), butylmethoxydibenzoylmethane, bisethylhexyloxyphenolmethoxyphenyltriazine, sinoxate, ethyldihydroxypro Pilfaba, octocrylene, ethylhexyldimethylfaba, ethylhexylmethoxycinnamate, ethylhexylsalicylate, ethylhexyltriazone, isoamyl-p-methoxycinnamate, polysilicon-15 (dimethicodiene Chilbenzalmalonate), terephthalily dendicamphor sulfonic acid and salts thereof, TEA-salicylate, and aminobenzoic acid (Pava).
또한, 본 발명의 화장료 조성물은 당업계에서 통상적으로 제조되는 어떠한 제형으로도 제조될 수 있으며, 예를 들어, 용액, 현탁액, 유탁액, 페이스트, 겔, 크림, 로션, 파우더, 비누, 계면활성제-함유 클렌징, 오일, 분말파운데이션, 유탁액 파운데이션, 왁스 파운데이션 및 스프레이 등으로 제형화될 수 있으나, 이에 한정되는 것은 아니다. 보다 상세하게는, 본 발명의 화장료 조성물은 유연 화장수, 영양 화장수, 영양 크림, 마사지 크림, 에센스, 아이 크림, 클렌징 크림, 클렌징 폼, 클렌징 워터, 팩, 스프레이 또는 파우더의 제형으로 제조될 수 있다.In addition, the cosmetic composition of the present invention may be prepared in any formulation conventionally prepared in the art, for example, solutions, suspensions, emulsions, pastes, gels, creams, lotions, powders, soaps, surfactants- It may be formulated as containing cleansing, oil, powder foundation, emulsion foundation, wax foundation, and spray, but is not limited thereto. More specifically, the cosmetic composition of the present invention may be prepared in the form of a flexible lotion, nutritional lotion, nutritional cream, massage cream, essence, eye cream, cleansing cream, cleansing foam, cleansing water, pack, spray or powder.
본 발명의 제형이 페이스트, 크림 또는 겔인 경우에는 담체 성분으로서 동물성유, 식물성유, 왁스, 파라핀, 전분, 트라칸트, 셀룰로오스 유도체, 폴리에틸렌 글리콜, 실리콘, 벤토나이트, 실리카, 탈크 또는 산화아연 등이 이용될 수 있다.When the formulation of the present invention is a paste, cream or gel, animal oil, vegetable oil, wax, paraffin, starch, tracant, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc, or zinc oxide may be used as a carrier component. I can.
본 발명의 제형이 용액 또는 유탁액인 경우에는 담체 성분으로서 용매, 용해화제 또는 유탁화제가 이용되고, 예컨대 물, 에탄올, 이소프로판올, 에틸 카보네이트, 에틸 아세테이트, 벤질 알코올, 벤질 벤조에이트, 프로필렌글리콜, 1,3-부틸글리콜 오일, 글리세롤 지방족 에스테르, 폴리에틸렌 글리콜 또는 소르비탄의 지방산 에스테르가 있다.When the formulation of the present invention is a solution or emulsion, a solvent, a solubilizing agent or an emulsifying agent is used as a carrier component, such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1 ,3-butylglycol oil, glycerol aliphatic ester, polyethylene glycol or fatty acid ester of sorbitan.
본 발명의 제형이 현탁액인 경우에는 담체 성분으로서 물, 에탄올 또는 프로필렌 글리콜과 같은 액상의 희석제, 에톡실화 이소스테아릴 알코올, 폴리옥시에틸렌 소르비톨 에스테르 및 폴리옥시에틸렌 소르비탄 에스테르와 같은 현탁제, 미소 결정성 셀룰로오스, 알루미늄 메타히드록시드, 벤토나이트, 아가 또는 트라칸트 등이 이용될 수 있다.When the formulation of the present invention is a suspension, as a carrier component, a liquid diluent such as water, ethanol or propylene glycol, an ethoxylated isostearyl alcohol, a suspending agent such as polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, microcrystals Sex cellulose, aluminum metahydroxide, bentonite, agar or tracanth, and the like can be used.
본 발명의 제형이 파우더 또는 스프레이인 경우에는 담체 성분으로서 락토스, 탈크, 실리카, 알루미늄 히드록시드, 칼슘 실리케이트 또는 폴리아미드 파우더가 이용될 수 있고, 특히 스프레이인 경우에는 추가적으로 클로로플루오로히드로카본, 프로판/부탄 또는 디메틸 에테르와 같은 추진체를 포함할 수 있다.When the formulation of the present invention is a powder or spray, lactose, talc, silica, aluminum hydroxide, calcium silicate, or polyamide powder may be used as a carrier component. In particular, in the case of a spray, additionally chlorofluorohydrocarbon, propane / May contain propellants such as butane or dimethyl ether.
본 발명의 제형이 계면활성제 함유 클렌징인 경우에는 담체 성분으로서 지방족 알코올 설페이트, 지방족 알코올에테르 설페이트, 설포숙신산 모노에스테르, 이세티오네이트, 이미다졸리늄 유도체, 메틸타우레이트, 사르코시네이트, 지방산 아미드 에테르 설페이트, 알킬아미도베타인, 지방족 알코올, 지방산 글리세리드, 지방산 디에탄올아미드, 식물성 유, 라놀린 유도체 또는 에톡실화 글리세롤 지방산 에스테르 등이 이용될 수 있다.When the formulation of the present invention is a surfactant-containing cleansing, as a carrier component, aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyltaurate, sarcosinate, fatty acid amide ether Sulfates, alkylamidobetaines, fatty alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, lanolin derivatives, or ethoxylated glycerol fatty acid esters may be used.
또한, 본 발명은 톱니모자반 및 폴록사머를 유효성분으로 포함하는 나노에멀젼 화장료 조성물을 인간의 피부에 적용하여 피부미백 효과를 갖는 것을 특징으로 하는 화장방법을 제공할 수 있다.In addition, the present invention can provide a cosmetic method, characterized in that it has a skin whitening effect by applying a nanoemulsion cosmetic composition comprising a sawtooth cap and poloxamer as active ingredients to human skin.
본 발명의 화장 방법은 본 발명의 화장료 조성물을 이용하는 모든 화장 방법을 일컫는다. 즉, 화장료 조성물을 이용하는 당업계에 공지된 모든 방법이 본 발명의 화장 방법에 속한다.The cosmetic method of the present invention refers to all cosmetic methods using the cosmetic composition of the present invention. That is, all methods known in the art using the cosmetic composition belong to the cosmetic method of the present invention.
본 발명의 화장료 조성물은 단독 또는 중복하여 사용하거나, 본 발명 이외의 다른 화장료 조성물과 중복하여 사용할 수 있다. 또한 본 발명에 따른 화장료 조성물은 통상적인 사용방법에 따라 사용될 수 있으며, 사용자의 피부 상태 또는 취향에 따라 그 사용횟수를 달리할 수 있다.The cosmetic composition of the present invention may be used alone or in duplicate, or may be used in conjunction with other cosmetic compositions other than the present invention. In addition, the cosmetic composition according to the present invention may be used according to a conventional method of use, and the number of times of use thereof may be varied according to a user's skin condition or taste.
또한 본 발명은, 톱니모자반(Sargassum serratifolium) 및 폴록사머(poloxamer)를 포함하는, 미백용 식품 조성물을 제공한다.In addition, the present invention provides a food composition for whitening, comprising a sawtooth cap (Sargassum serratifolium) and poloxamer (poloxamer).
본 발명의 식품 조성물은 유효성분인 톱니모자반 및 폴록사머를 함유하는 것 외에 통상의 식품 조성물과 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다.The food composition of the present invention may contain various flavoring agents or natural carbohydrates, etc. as an additional component, as in a conventional food composition, in addition to containing the active ingredients, such as sawtooth hatch and poloxamer.
상술한 천연 탄수화물의 예는 모노사카라이드, 예를 들어, 포도당, 과당 등; 디사카라이드, 예를 들어 말토스, 슈크로스 등; 및 폴리사카라이드, 예를 들어 덱스트린, 시클로덱스트린 등과 같은 통상적인 당, 및 자일리톨,소르비톨, 에리트리톨 등의 당알콜이다. 상술한 향미제는 천연 향미제 (타우마틴), 스테비아 추출물(예를 들어 레바우디오시드 A, 글리시르히진 등) 및 합성 향미제 (사카린, 아스파르탐 등)를 유리하게 사용할 수 있다.Examples of the above-described natural carbohydrates include monosaccharides such as glucose, fructose, and the like; Disaccharides such as maltose, sucrose, and the like; And polysaccharides, for example, common sugars such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol. The above-described flavoring agent can be advantageously used as a natural flavoring agent (taumatin), stevia extract (eg, rebaudioside A, glycyrrhizin, etc.), and synthetic flavoring agents (saccharin, aspartame, etc.).
본 발명의 식품 조성물은 상기 화장료 조성물과 동일한 방식으로 제제화되어 기능성 식품으로 이용하거나, 각종 식품에 첨가할 수 있다. 본 발명의 조성물을 첨가할 수 있는 식품으로는 예를 들어, 음료류, 육류, 초코렛, 식품류, 과자류, 피자, 라면, 기타 면류, 껌류, 사탕류, 아이스크림류, 알코올 음료류, 비타민 복합제 및 건강보조식품류 등이 있다.The food composition of the present invention may be formulated in the same manner as the cosmetic composition and used as a functional food or added to various foods. Foods to which the composition of the present invention can be added include, for example, beverages, meat, chocolate, foods, confectionery, pizza, ramen, other noodles, gums, candy, ice cream, alcoholic beverages, vitamin complexes and health supplements, etc. There is this.
또한 상기 식품 조성물은 유효성분인 추출물 외에 여러 가지 영양제, 비타민, 광물 (전해질), 합성 풍미제 및 천연 풍미제 등의 풍미제, 착색제 및 중진제 (치즈, 초콜릿 등), 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알콜, 탄산음료에 사용되는 탄산화제 등을 함유할 수 있다. 그밖에 본 발명의 식품 조성물은 천연 과일 쥬스 및 과일 쥬스 음료 및 야채 음료의 제조를 위한 과육을 함유할 수 있다.In addition, the food composition includes various nutrients, vitamins, minerals (electrolytes), flavoring agents such as synthetic flavoring and natural flavoring agents, coloring agents and thickeners (cheese, chocolate, etc.), pectic acid and salts thereof, in addition to the extract as an active ingredient. Alginic acid and salts thereof, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonates used in carbonated beverages, and the like may be contained. In addition, the food composition of the present invention may contain flesh for the production of natural fruit juice and fruit juice beverages and vegetable beverages.
또한 본 발명은, (1)톱니모자반(Sargassum serratifolium)을 추출하는 단계;In addition, the present invention, (1) the step of extracting the serratus (Sargassum serratifolium);
(2)상기 톱니모자반 추출물에 폴록사머(poloxamer)를 추가하는 단계;(2) adding a poloxamer to the sawtooth capillary extract;
및And
(3) 상기 (2) 단계에 지용성 성분을 더 추가하여 나노에멀젼을 생성하는 단계;를 포함하는, 미백용 화장료 조성물의 제조방법을 제공한다.(3) generating a nanoemulsion by adding a fat-soluble component to the (2) step; containing, it provides a method for producing a cosmetic composition for whitening.
이하 본 발명을, 실시예를 통하여 보다 구체적으로 설명한다. Hereinafter, the present invention will be described in more detail through examples.
다만, 하기 실시예는 본 발명의 기술적 특징을 명확하게 예시하기 위한 것 일뿐, 본 발명의 보호범위를 한정하는 것은 아니다.However, the following examples are only intended to clearly illustrate the technical features of the present invention, and do not limit the protection scope of the present invention.
<준비예1> 톱니모자반 에탄올 추출물의 제조<Preparation Example 1> Preparation of ethanol extract of sawtooth hatch
본 발명에 사용한 톱니모자반은 부산시 기장군에서 자생하는 천연산을 스쿠버를 동원하여 채취하였고, 기장산의 종확인은 부경대학교 생태공학과 최창근 교수가 수행하였다. 톱니모자반을 양지에서 자연건조 후, 마쇄하여 얻은 분말 2kg을 95% 에탄올 8 L에 넣고 70℃에서 3시간 3회 반복하여 환류냉각 추출한 후, 한외여과기(니또덴꼬, 일본)로 이물질을 제거하였다. 여과 추출물은 진공회전농축기로 40℃에서 에탄올을 제거한 후, 추출된 잔사로서 조추출물 200±25g을 수득하였다. 이렇게 수득한 톱니모자반 에탄올 추출물은 4℃온도에서 냉장보관하면서 나노에멀젼의 제조, 미백효과 확인 및 세포독성 평가에 사용하였다.The sawtooth hat plate used in the present invention was harvested by scuba mobilizing a natural product that grows in Gijang-gun, Busan, and the species identification of Gijang-san was performed by Professor Chang-geun Choi of the Department of Ecological Engineering, Pukyong National University. After natural drying of the sawtooth hatch in a sunny place, 2 kg of the powder obtained by grinding was added to 8 L of 95% ethanol and extracted with reflux cooling by repeating 3 times at 70° C. for 3 hours, and then foreign matter was removed with an ultrafilter (Nitto Denko, Japan). After removing ethanol at 40°C with a vacuum rotary concentrator, the filtered extract was obtained as 200±25 g of a crude extract as an extracted residue. The ethanol extract obtained in this way was used to prepare a nanoemulsion, check the whitening effect, and evaluate cytotoxicity while refrigerated at 4°C.
<실시예 1~4> 토코페놀 농도에 따른 나노에멀젼의 크기<Examples 1 to 4> Size of nanoemulsion according to tocophenol concentration
본 발명에서, 토코페놀 농도에 따른 나노에멀젼의 크기를 확인하기 위하여, 톱니모자반 에탄올 추출물 0.5 g을 토코페놀 0 내지 0.1 g의 농도로 4.5 ml의 에탄올과 혼합하여, 폴리옥실-35-캐스터오일 1g 과 혼합하여, 지용성 혼합물을 제조하였다. 제조된 지용성 혼합물을, 증류수 100 ml에 분사하여, 나노에멀젼을 제조하였으며, 그 결과를 도 1에 나타내었다. 그 결과, 토코페놀의 농도가 0 g(실시예 1, 도 1A), 0.02 g(실시예 2, 도 1B) 0.05 g(실시예 3, 도 1C), 0.1 g(실시예 4, 도 1D)로 농도가 변하였음에도, 나노에멀젼의 크기는 19 내지 20 nm의 범위로 유의적인 차이를 보이지 않았다. In the present invention, in order to confirm the size of the nanoemulsion according to the concentration of tocophenol, 0.5 g of ethanol extract of sawtooth hatch was mixed with 4.5 ml of ethanol at a concentration of 0 to 0.1 g of tocophenol, and 1 g of polyoxyl-35-caster oil Mixed with, to prepare a fat-soluble mixture. The prepared fat-soluble mixture was sprayed into 100 ml of distilled water to prepare a nanoemulsion, and the results are shown in FIG. 1. As a result, the concentration of tocophenol was 0 g (Example 1, FIG. 1A), 0.02 g (Example 2, FIG. 1B) 0.05 g (Example 3, FIG. 1C), 0.1 g (Example 4, FIG. 1D) Even though the concentration was changed, the size of the nanoemulsion did not show a significant difference in the range of 19 to 20 nm.
<실시예 5~8> 에탄올 농도에 따른 나노에멀젼의 크기<Examples 5 to 8> Size of nanoemulsion according to ethanol concentration
본 발명에서, 에탄올 농도에 따른 나노에멀젼의 크기를 확인하기 위하여, 톱니모자반 에탄올 추출물 0.5 g을 2 내지 19.5 ml의 에탄올에 희석하고, 폴리옥실-35-캐스터오일 1 g과 혼합하여 지용성 성분을 제조한 후, 증류수 100 ml에 분사하여, 나노에멀젼을 제조하였다. 그 결과, 에탄올의 농도가 2 ml일 때 29.01 nm의 입자크기를 가졌으며(실시예 5, 도 2A), 4.5 일 때 20.22 nm로 가장 작은 입자크기를 나타낸 것을 확인하였다(실시예 6, 도 2B). 추가적으로, 에탄올의 농도가 9.5 ml 및 19.5 ml로 첨가되었을 때에는 각각 31.30 및 72.61 nm로 확인 되었다(실시예 7 및 실시예 8, 도 2C 및 도 2D).In the present invention, in order to confirm the size of the nanoemulsion according to the ethanol concentration, 0.5 g of the ethanol extract of the sawtooth hatch was diluted in 2 to 19.5 ml of ethanol, and a fat-soluble component was prepared by mixing with 1 g of polyoxyl-35-castor oil. After that, it was sprayed into 100 ml of distilled water to prepare a nanoemulsion. As a result, it was confirmed that when the ethanol concentration was 2 ml, it had a particle size of 29.01 nm (Example 5, Fig. 2A), and when 4.5, the smallest particle size was 20.22 nm (Example 6, Fig. 2B). ). In addition, when the concentration of ethanol was added at 9.5 ml and 19.5 ml, it was found to be 31.30 and 72.61 nm, respectively (Example 7 and Example 8, FIGS. 2C and 2D).
<실시예 9~10> PEG첨가에 유무에 따른 나노에멀젼의 크기<Examples 9-10> Size of nanoemulsion according to the presence or absence of PEG addition
본 발명에서, PEG첨가에 따른 나노에멀젼의 크기를 비교하기 위하여, 톱니모자반 에탄올 추출물 0.5 g을 4.5 ml의 에탄올을 이용하여 희석하고, PEG400을 0 또는 0.3 g첨가하여, 폴리옥실-40-하이드로제네이티드캐스터오일 1.25 g 과 혼합하여 지용성 성분을 제조하고, 플록사머 407 0.6 g이 혼합된 증류수 100 ml에 분사하여, 나노에멀젼을 제조하였다. 그 결과, PEG가 첨가되지 않았을 때에는 23.03 nm의 입자크기를 가졌으며(실시예 9, 도 3A), PEG가 첨가 되었을 때 21.61 nm로 입자크기가 작아진 것을 확인하였다(실시예 10, 도 3B).In the present invention, in order to compare the size of the nanoemulsion according to the addition of PEG, 0.5 g of the ethanol extract of sawtooth hatch was diluted with 4.5 ml of ethanol, and 0 or 0.3 g of PEG400 was added, and polyoxyl-40-hydrogenei A fat-soluble component was prepared by mixing with 1.25 g of Tiedcaster oil, and sprayed into 100 ml of distilled water in which 0.6 g of Phloxamer 407 was mixed to prepare a nanoemulsion. As a result, it was confirmed that when PEG was not added, the particle size was 23.03 nm (Example 9, Fig. 3A), and when PEG was added, the particle size decreased to 21.61 nm (Example 10, Fig. 3B). .
<실시예 11~13> 폴록사머 종류에 따른 나노에멀젼의 크기<Examples 11 to 13> Size of the nanoemulsion according to the type of poloxamer
본 발명에서, 폴록사머 종류에 따른 나노에멀젼의 크기를 비교하기 위하여, 폴록사머 407, 폴록사머 188, 폴록사머 338을 각각 1 g씩 100 ml의 증류수에 혼합하여 수용액을 제조하였다. 그 후 톱니모자반 에탄올 추출물 0.5 g을 4.5 ml의 에탄올에 희석하고, 토코페놀 0.1 g, PEG400 0.3 g과 함께 폴리옥실-35-캐스터오일 1.25 g에 혼합하여 지용성 성분을 제조하였다. 제조된 지용성 성분을 상기의 수용액에 각각 분사하여, 나노에멀젼을 제조하였으며, 그 결과를 도 4에 나타내었다. 그 결과, 폴록사머 188이 첨가된 나노에멀젼의 크기는 14.83 nm의 가장 작은 입자크기 가졌으며(실시예 12, 도 4B), 폴록사머 407은 17.32 nm(실시예 11,도 4A), 폴록사머 338은 20.32 nm(실시예 13, 도 4C)의 크기를 가지는 입자가 생성되었다.In the present invention, in order to compare the size of the nanoemulsion according to the type of poloxamer, an aqueous solution was prepared by mixing poloxamer 407, poloxamer 188, and poloxamer 338 each 1 g in 100 ml of distilled water. Then, 0.5 g of the ethanol extract of sawtooth capillary was diluted in 4.5 ml of ethanol and mixed with 0.1 g of tocophenol and 0.3 g of PEG400 in 1.25 g of polyoxyl-35-castor oil to prepare a fat-soluble component. Each of the prepared fat-soluble components was sprayed into the aqueous solution to prepare a nanoemulsion, and the results are shown in FIG. As a result, the size of the nanoemulsion to which poloxamer 188 was added had the smallest particle size of 14.83 nm (Example 12, Fig. 4B), poloxamer 407 was 17.32 nm (Example 11, Fig. 4A), and poloxamer 338 A particle having a size of 20.32 nm (Example 13, Fig. 4C) was produced.
<실시예 14> 저장안정성 시험<Example 14> Storage stability test
본 발명에서, 실시예 11 내지 13에서 제조된 나노에멀젼의 안전성을 평가하기 위하여, 제조된 나노에멀젼을 싸이클쳄버에 넣어서 저장안정성을 분석하였다. 싸이클쳄버의 저장 조건은 -15, 0, 5, 15, 25, 35, 45 ℃에서 각각 24시간씩 5 싸이클 저장한 후 탁도를 층정하였다. 측정한 결과 침전물은 생성되지 않은 것으로 나타났다(도 5).In the present invention, in order to evaluate the safety of the nanoemulsions prepared in Examples 11 to 13, the prepared nanoemulsions were placed in a cycle chamber to analyze storage stability. The storage conditions of the cycle chamber were stored for 5 cycles for 24 hours at -15, 0, 5, 15, 25, 35, and 45°C, respectively, and the turbidity was layered. As a result of the measurement, it was found that no precipitate was formed (FIG. 5).
<실시예 15> 세포독성 시험<Example 15> Cytotoxicity test
본 발명에서, 실시예 11 내지 실시예 13에서 제조된 나노에멀젼의 세포독성을 평가하기 위하여, 제조된 나노에멀젼을 0, 5, 10, 15, 20 μg/ml의 농도로 B16F10 세포에 처리하여 세포 생존율을 통한 세포독성을 평가하였다. 세포생존율을 MTS kit를 사용하여 분석하였다. 더욱 자세하게는 12 well plate에 B16F10 세포를 6 x 103 cell 농도로 세포를 분주하여 24 시간 배양 후, 각각의 나노에멀젼을 농도별로 1시간 동안 전처리 한 뒤, α-MSH 1 μM로 24 시간 처리 및 배양 후, 95 μl의 배지와 5 μl의 MTS 용액을 가한 뒤 3시간 후 490 nm에서 흡광도를 측정하였다.In the present invention, in order to evaluate the cytotoxicity of the nanoemulsions prepared in Examples 11 to 13, the prepared nanoemulsions were treated with B16F10 cells at a concentration of 0, 5, 10, 15, and 20 μg/ml to Cytotoxicity through viability was evaluated. Cell viability was analyzed using the MTS kit. In more detail, B16F10 cells were dispensed into a 12 well plate at a concentration of 6 x 10 3 cells, cultured for 24 hours, each nanoemulsion was pretreated for 1 hour at each concentration, and then treated with α-
그 결과, 본 발명에서 제조된 나노에멀젼은 20 μg/mL이하의 농도범위에서 세포독성이 나타나지 않음을 확인하였다(도 6).As a result, it was confirmed that the nanoemulsion prepared in the present invention did not show cytotoxicity in the concentration range of 20 μg/mL or less (FIG. 6).
<실시예 16> 나노에멀젼의 B16F10세포에 대한 멜라닌 생합성 저해 효과<Example 16> Inhibitory effect of nanoemulsion on melanin biosynthesis on B16F10 cells
본 발명에서 나노에멀젼이 멜라닌 생합성에 미치는 영향을 알아보기 위하여 B16F10 세포에 실시예 11 내지 실시예 13의 방법대로 제조된 나노에멀젼을 농도별로 처리하고 세포 내 멜라닌 함량을 측정하였다. 보다 자세하게는 B16F10세포를 12 well plate에 well당 8 x 104 세포로 분주한 후 24시간 뒤 나노에멀젼을 농도별로 1시간 동안 전처리한 뒤, α-MSH 1 μM로 72시간 동안 처리하고 72시간 뒤에 PBS로 2번 세척하였다. 세척된 세포는 1N NaOH로 세포를 파쇄한 후 EP 튜브에 담아서 30분간 60℃에서 가열하였다. 세포 용해물을 5000 x g에서 5분간 원심분리한 후 상층액의 흡광도를 405 nm에서 측정하였다. 그 결과를 도 7에 나타내었다. 본 발명의 실시예 11, 12 및 13의 방법으로 제조된 나노에멀젼은 모두, B16F10세포에서 멜라닌 생합성을 100% 저해하는 것을 확인하였으며, 저장 기한이 증가하여도(0 내지 5 cycle), 멜라닌 생합성 억제에는 큰 변화가 없어, 저장 안정성 또한 입증할 수 있었다. In the present invention, in order to examine the effect of the nanoemulsion on melanin biosynthesis, the nanoemulsion prepared according to the method of Examples 11 to 13 was treated with each concentration in B16F10 cells and the melanin content in the cell was measured. In more detail, after dispensing B16F10 cells into a 12 well plate at 8 x 10 4 cells per well, after 24 hours, the nanoemulsion was pretreated for 1 hour by concentration, and then treated with α-
Claims (9)
(2)상기 톱니모자반 추출물에 폴록사머(poloxamer)를 추가하는 단계;
및
(3) 상기 (2) 단계에 지용성 성분을 더 추가하여 나노에멀젼을 생성하는 단계;를 포함하는, 미백용 화장료 조성물의 제조방법.(1) Extracting the serratus plaque (Sargassum serratifolium);
(2) adding a poloxamer to the sawtooth capillary extract;
And
(3) generating a nanoemulsion by adding a fat-soluble component to the (2) step; containing, a method for producing a cosmetic composition for whitening.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020190141947A KR102320918B1 (en) | 2019-11-07 | 2019-11-07 | Whitening cosmetic composition comprising Sargassum serratifolium and poloxamer and use thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020190141947A KR102320918B1 (en) | 2019-11-07 | 2019-11-07 | Whitening cosmetic composition comprising Sargassum serratifolium and poloxamer and use thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20210055469A true KR20210055469A (en) | 2021-05-17 |
KR102320918B1 KR102320918B1 (en) | 2021-11-02 |
Family
ID=76158379
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020190141947A KR102320918B1 (en) | 2019-11-07 | 2019-11-07 | Whitening cosmetic composition comprising Sargassum serratifolium and poloxamer and use thereof |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR102320918B1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102604090B1 (en) * | 2022-11-15 | 2023-11-21 | 한국콜마주식회사 | cosmetic composition for UV protection with stabilized poorly soluble ingredients |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100562348B1 (en) | 2002-09-09 | 2007-04-12 | (주)스피어테크 | The ethanol extract from Ephedra sinica Stapf which have ability of whitening, anti-wrinkle and anti-aging effect in the cosmetic |
KR100850686B1 (en) | 2007-03-27 | 2008-08-07 | 인하대학교 산학협력단 | Extract of nigella glandulifera freyn et sint having whitening activity and the cosmetic composition comprising thereof |
KR20090073368A (en) * | 2007-12-31 | 2009-07-03 | (주)아모레퍼시픽 | A stable nano-emulsion with narrow particle size distribution |
KR20110006444A (en) * | 2009-07-14 | 2011-01-20 | 한불화장품주식회사 | Sargassum sp. extract that have low photo-induced cytotoxicity, preparation method thereof and cosmetic composition containing the same |
KR101644753B1 (en) * | 2015-08-07 | 2016-08-01 | 부경대학교 산학협력단 | Cosmetic composition comprising Sargassum serratifolium extract for skin whitening |
KR20180118563A (en) * | 2017-04-21 | 2018-10-31 | 유씨엘 주식회사 | Nano-emulsion containing peptide and seaweeds extracts and cosmetic composition using the same |
-
2019
- 2019-11-07 KR KR1020190141947A patent/KR102320918B1/en active IP Right Grant
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100562348B1 (en) | 2002-09-09 | 2007-04-12 | (주)스피어테크 | The ethanol extract from Ephedra sinica Stapf which have ability of whitening, anti-wrinkle and anti-aging effect in the cosmetic |
KR100850686B1 (en) | 2007-03-27 | 2008-08-07 | 인하대학교 산학협력단 | Extract of nigella glandulifera freyn et sint having whitening activity and the cosmetic composition comprising thereof |
KR20090073368A (en) * | 2007-12-31 | 2009-07-03 | (주)아모레퍼시픽 | A stable nano-emulsion with narrow particle size distribution |
KR20110006444A (en) * | 2009-07-14 | 2011-01-20 | 한불화장품주식회사 | Sargassum sp. extract that have low photo-induced cytotoxicity, preparation method thereof and cosmetic composition containing the same |
KR101644753B1 (en) * | 2015-08-07 | 2016-08-01 | 부경대학교 산학협력단 | Cosmetic composition comprising Sargassum serratifolium extract for skin whitening |
KR20180118563A (en) * | 2017-04-21 | 2018-10-31 | 유씨엘 주식회사 | Nano-emulsion containing peptide and seaweeds extracts and cosmetic composition using the same |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102604090B1 (en) * | 2022-11-15 | 2023-11-21 | 한국콜마주식회사 | cosmetic composition for UV protection with stabilized poorly soluble ingredients |
Also Published As
Publication number | Publication date |
---|---|
KR102320918B1 (en) | 2021-11-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101835739B1 (en) | Composition comprising extracts or fractions of Artemisia capillaris as an effective ingredient | |
KR102431443B1 (en) | Composition for improving skin wrinkles and elasticity containing the extract of Hibiseu Smanihot L. | |
KR20160123732A (en) | Cosmetic composition comprising the extract of cynara scolymus and brassica oleracea var. botrytis as active ingredient | |
KR101071414B1 (en) | Composition for Whitening Containing Extract of Annona muricata as an active ingredient | |
KR102320918B1 (en) | Whitening cosmetic composition comprising Sargassum serratifolium and poloxamer and use thereof | |
KR102472974B1 (en) | Composition for improving skin | |
KR101772494B1 (en) | COMPOSITION OF SKIN WHITENING CONTAINING EXTRACT OF Sargassum horneri AND METHOD OF MAKING THE SAME | |
KR102351766B1 (en) | Methods for the preparation of nanoemulsion containing skin-whitening, anti-wrinkle and anti-inflammatory cosmetic composition and use thereof | |
KR20170050254A (en) | Method for producing extract of Selaginella tamariscina with enhanced extraction yield using ultra high-pressure homogenization | |
JP3933535B2 (en) | Cell activator | |
KR20110085657A (en) | Composition for skin whitening comprising extracts of veronica longiofolia l. | |
KR20160036123A (en) | Cosmetic composition containing extracts consisting of Tremella fuciformis Berk., Caulerpa lentillifera J. Agardh, Trichosanthes kirilowii Maxim, Camellia Sinensis, Nelumbo nucifera Gaertn., Helichrysum angustifolium DC., and colloidal gold | |
KR20100042086A (en) | Composition for whitening containing extract of cortex cinnamomi cassiae | |
KR20210134284A (en) | Composition for improving skin comprising an extract of Pueraria thomsonii or a compound derived therefrom | |
KR102212343B1 (en) | Composition for skin anti-aging or moisturization comprising extract of marian plum | |
KR101860001B1 (en) | Cosmetic composition comprising bamboo stem extract as an active ingredient | |
KR20100042090A (en) | Composition for whitening containing extract of jasminum grandiflorum | |
KR20100043717A (en) | Composition for whitening containing extract of ixora coccinea | |
KR102061333B1 (en) | Antioxidant composition comprising fraction of defatted perilla extract as effective component | |
KR101079713B1 (en) | Composition for Whitening Containing Extract of Talinum crassifolium as an active ingredient | |
KR102416777B1 (en) | Composition comprising Carex scabrifolia extract | |
KR102651353B1 (en) | Composition for anti-oxidation and whitening comprising golden crocus extract, and use thereof | |
KR102290291B1 (en) | Composition for improving moisturizing skin containing fermented blueberry and black rice extracts | |
KR102326086B1 (en) | Composition for Improving Skin Conditions Having Skin Whitening, Moisturizing, Anti-Wrinkle and Skin Barrier Property Comprising Complex Extracts of Broussonetia kazinoki as Active Ingredient | |
KR102453959B1 (en) | Cosmetic composition comprising Castanopsis sieboldii leaves extract or its fraction as an active ingredient |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant |